{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:51Z","timestamp":1792075551180,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03809-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:26:28Z","timestamp":1784125588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant"],"prefix":"10.1186","volume":"27","author":[{"given":"Toby M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Funke-Chambour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"3809_CR1","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-64.","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"3809_CR2","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.","journal-title":"Nat Rev Dis Primers."},{"key":"3809_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347.","journal-title":"Am J Respir Crit Care Med."},{"key":"3809_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655\u201365.","journal-title":"JAMA."},{"key":"3809_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066354","volume":"377","author":"GY Liu","year":"2022","unstructured":"Liu GY, Budinger GRS, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. 2022;377:e066354.","journal-title":"BMJ"},{"key":"3809_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020","author":"KK Brown","year":"2020","unstructured":"Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00085-2020.","journal-title":"Eur Respir J"},{"key":"3809_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s12325-019-00992-9","volume":"36","author":"TM Maher","year":"2019","unstructured":"Maher TM, Wuyts W. Management of fibrosing interstitial lung diseases. Adv Ther. 2019;36:1518\u201331.","journal-title":"Adv Ther."},{"key":"3809_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12931-022-01980-4","volume":"23","author":"BE Decato","year":"2022","unstructured":"Decato BE, Leeming DJ, Sand JMB, Fischer A, Du S, Palmer SM, et al. LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respir Res. 2022;23:61.","journal-title":"Respir Res."},{"key":"3809_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","volume":"14","author":"AM Tager","year":"2008","unstructured":"Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14:45\u201354.","journal-title":"Nat Med."},{"key":"3809_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1165\/rcmb.2010-0155OC","volume":"46","author":"M Funke","year":"2012","unstructured":"Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol. 2012;46:355\u201364.","journal-title":"Am J Respir Cell Mol Biol."},{"key":"3809_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.115885","volume":"438","author":"MW Gill","year":"2022","unstructured":"Gill MW, Murphy BJ, Cheng PTW, Sivaraman L, Davis M, Lehman-McKeeman L. Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278. Toxicol Appl Pharmacol. 2022;438:115885.","journal-title":"Toxicol Appl Pharmacol."},{"key":"3809_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","volume":"154","author":"SM Palmer","year":"2018","unstructured":"Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, et al. Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest. 2018;154:1061\u20139.","journal-title":"Chest."},{"key":"3809_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115846","volume":"438","author":"L Sivaraman","year":"2022","unstructured":"Sivaraman L, Gill M, Nelson DM, Chadwick KD. Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists. Toxicol Appl Pharmacol. 2022;438:115846.","journal-title":"Toxicol Appl Pharmacol."},{"key":"3809_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","volume":"211","author":"TJ Corte","year":"2025","unstructured":"Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. Efficacy and safety of admilparant, an LPA1 antagonist in pulmonary fibrosis: a phase 2 randomized clinical trial. Am J Respir Crit Care Med. 2025;211:230\u20138.","journal-title":"Am J Respir Crit Care Med."},{"key":"3809_CR15","doi-asserted-by":"publisher","unstructured":"Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021;8:e001026. https:\/\/doi.org\/10.1136\/bmjresp-2021-001026.","DOI":"10.1136\/bmjresp-2021-001026"},{"key":"3809_CR16","doi-asserted-by":"publisher","first-page":"L487","DOI":"10.1152\/ajplung.00037.2024","volume":"327","author":"J Nemeth","year":"2024","unstructured":"Nemeth J, Skronska-Wasek W, Keppler S, Schundner A, Gross A, Schoenberger T, et al. Adiponectin suppresses stiffness-dependent, profibrotic activation of lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2024;327:L487\u2013502.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3809_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680997","volume":"8","author":"WS Bowman","year":"2021","unstructured":"Bowman WS, Echt GA, Oldham JM. Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response. Front Med (Lausanne). 2021;8:680997.","journal-title":"Front Med (Lausanne)."},{"key":"3809_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/resp.14543","volume":"28","author":"D Kalafatis","year":"2023","unstructured":"Kalafatis D, Joshua V, Hansson M, Mathsson-Alm L, Hensvold A, Skold M. Presence of anti-modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. 2023;28:925\u201333.","journal-title":"Respirology"},{"key":"3809_CR19","doi-asserted-by":"publisher","unstructured":"Majewski S, Szewczyk K, Zal A, Bialas AJ, Milkowska-Dymanowska J, Piotrowski WJ. Serial measurements of circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study. J Clin Med. 2021;10:3864. https:\/\/doi.org\/10.3390\/jcm10173864.","DOI":"10.3390\/jcm10173864"},{"key":"3809_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174547","volume":"12","author":"S Ohta","year":"2017","unstructured":"Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017;12:e0174547.","journal-title":"PLoS One"},{"key":"3809_CR21","doi-asserted-by":"publisher","first-page":"22977","DOI":"10.1038\/s41598-023-49180-4","volume":"13","author":"M Okamoto","year":"2023","unstructured":"Okamoto M, Fujimoto K, Johkoh T, Kawaguchi A, Mukae H, Sakamoto N, et al. A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib. Sci Rep. 2023;13:22977.","journal-title":"Sci Rep."},{"key":"3809_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311357","volume":"19","author":"M d'Alessandro","year":"2024","unstructured":"d\u2019Alessandro M, Cameli P, Cotton CV, Lamb JA, Bergantini L, Gangi S, et al. Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease. PLoS One. 2024;19:e0311357.","journal-title":"PLoS One."},{"key":"3809_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116270","volume":"172","author":"Y Sun","year":"2024","unstructured":"Sun Y, Ren Y, Song LY, Wang YY, Li TG, Wu YL, et al. Targeting iron-metabolism:a potential therapeutic strategy for pulmonary fibrosis. Biomed Pharmacother. 2024;172:116270.","journal-title":"Biomed Pharmacother"},{"key":"3809_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-021-01801-0","volume":"22","author":"H Jessen","year":"2021","unstructured":"Jessen H, Hoyer N, Prior TS, Frederiksen P, Karsdal MA, Leeming DJ, et al. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2021;22:205.","journal-title":"Respir Res."},{"key":"3809_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12890-021-01684-3","volume":"21","author":"H Jessen","year":"2021","unstructured":"Jessen H, Hoyer N, Prior TS, Frederiksen P, Ronnow SR, Karsdal MA, et al. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulm Med. 2021;21:382.","journal-title":"BMC Pulm Med."},{"key":"3809_CR26","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41467-020-15647-5","volume":"11","author":"T Tsukui","year":"2020","unstructured":"Tsukui T, Sun KH, Wetter JB, Wilson-Kanamori JR, Hazelwood LA, Henderson NC, et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun. 2020;11:1920.","journal-title":"Nat Commun."},{"key":"3809_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01181-2021","author":"B Clynick","year":"2022","unstructured":"Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.01181-2021.","journal-title":"Eur Respir J"},{"key":"3809_CR28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5:946\u201355.","journal-title":"Lancet Respir Med."},{"key":"3809_CR29","first-page":"1031","volume":"8","author":"H Fang","year":"2018","unstructured":"Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8:1031\u201363.","journal-title":"Adiponectin regulation and function. Compr Physiol."},{"key":"3809_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/JME-17-0096","volume":"59","author":"P Ahlstrom","year":"2017","unstructured":"Ahlstrom P, Rai E, Chakma S, Cho HH, Rengasamy P, Sweeney G. Adiponectin improves insulin sensitivity via activation of autophagic flux. J Mol Endocrinol. 2017;59:339\u201350.","journal-title":"J Mol Endocrinol."},{"key":"3809_CR31","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.1038\/s41598-018-29901-w","volume":"8","author":"T Yamashita","year":"2018","unstructured":"Yamashita T, Lakota K, Taniguchi T, Yoshizaki A, Sato S, Hong W, et al. An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. Sci Rep. 2018;8:11843.","journal-title":"Sci Rep."},{"key":"3809_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12890-025-03706-w","volume":"25","author":"E Nigro","year":"2025","unstructured":"Nigro E, D\u2019Agnano V, Pagliaro R, Mallardo M, Bianco A, Picone C, et al. Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study. BMC Pulm Med. 2025;25:263.","journal-title":"BMC Pulm Med."},{"key":"3809_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1983","volume":"6","author":"TS Adams","year":"2020","unstructured":"Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv. 2020;6:eaba1983.","journal-title":"Sci Adv"},{"key":"3809_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.5858\/2009-0144-OA.1","volume":"134","author":"S Fujishima","year":"2010","unstructured":"Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med. 2010;134:1136\u201342.","journal-title":"Arch Pathol Lab Med."},{"key":"3809_CR35","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1073\/pnas.092134099","volume":"99","author":"F Zuo","year":"2002","unstructured":"Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A. 2002;99:6292\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"3809_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2466-14-120","volume":"14","author":"S Estany","year":"2014","unstructured":"Estany S, Vicens-Zygmunt V, Llatjos R, Montes A, Penin R, Escobar I, et al. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGF\u03b21. BMC Pulm Med. 2014;14:120.","journal-title":"BMC Pulm Med."},{"key":"3809_CR37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01612-2021","author":"FA Khan","year":"2022","unstructured":"Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.01612-2021.","journal-title":"Eur Respir J"},{"key":"3809_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1164\/rccm.201101-0058OC","volume":"185","author":"TJ Richards","year":"2012","unstructured":"Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:67\u201376.","journal-title":"Am J Respir Crit Care Med."},{"key":"3809_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050093","volume":"5","author":"IO Rosas","year":"2008","unstructured":"Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.","journal-title":"PLoS Med."},{"key":"3809_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(24)00147-4","volume":"12","author":"HP Fainberg","year":"2024","unstructured":"Fainberg HP, Moodley Y, Triguero I, Corte TJ, Sand JMB, Leeming DJ, et al. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation. Lancet Respir Med. 2024;12:681\u201392.","journal-title":"Lancet Respir Med."},{"key":"3809_CR41","doi-asserted-by":"publisher","unstructured":"Ballester B, Milara J, Montero P, Cortijo J. MUC16 is overexpressed in idiopathic pulmonary fibrosis and induces fibrotic responses mediated by transforming growth factor-\u03b21 canonical pathway. Int J Mol Sci. 2021;22:6502. https:\/\/doi.org\/10.3390\/ijms22126502.","DOI":"10.3390\/ijms22126502"},{"key":"3809_CR42","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/cimb46090575","volume":"46","author":"K Omori","year":"2024","unstructured":"Omori K, Takada A, Toyomasu Y, Tawara I, Shintoku C, Imanaka-Yoshida K, et al. Expression of tenascin-C is upregulated in the early stages of radiation pneumonitis\/fibrosis in a novel mouse model. Curr Issues Mol Biol. 2024;46:9674\u201385.","journal-title":"Curr Issues Mol Biol"},{"key":"3809_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdev.2024.203941","volume":"179","author":"Y Sun","year":"2024","unstructured":"Sun Y, King B, Hamlin AJ, Saniepay M, Gorshkov K, Barker G, et al. Identification of a fibronectin-binding protein signature associated with idiopathic pulmonary fibrosis. Cells Dev. 2024;179:203941.","journal-title":"Cells Dev"},{"key":"3809_CR44","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2147\/CCID.S461760","volume":"17","author":"W Xiang","year":"2024","unstructured":"Xiang W, Guo Z, Zhang Y, Xu Y. The role of tenascin-C in hypertrophic scar formation: insights from cell and animal experiments. Clin Cosmet Investig Dermatol. 2024;17:1637\u201348.","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"3809_CR45","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.chest.2020.04.066","volume":"158","author":"A Adegunsoye","year":"2020","unstructured":"Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, et al. Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis. Chest. 2020;158:1526\u201334.","journal-title":"Chest."},{"key":"3809_CR46","doi-asserted-by":"crossref","unstructured":"Politis-Barber V, Petrick HL, Raajendiran A, DesOrmeaux GJ, Brunetta HS, Dos Reis LM, et al. Ckmt1 is dispensable for mitochondrial bioenergetics within white\/beige adipose tissue. Function (Oxf). 2022;3:zqac037.","DOI":"10.1093\/function\/zqac037"},{"key":"3809_CR47","doi-asserted-by":"publisher","first-page":"30030","DOI":"10.1038\/srep30030","volume":"6","author":"S M\u00fcller","year":"2016","unstructured":"M\u00fcller S, Balaz M, Stefanicka P, Varga L, Amri EZ, Ukropec J, et al. Proteomic analysis of human brown adipose tissue reveals utilization of coupled and uncoupled energy expenditure pathways. Sci Rep. 2016;6:30030.","journal-title":"Sci Rep."},{"key":"3809_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3892\/ijmm.2010.566","volume":"27","author":"PA Svensson","year":"2011","unstructured":"Svensson PA, Jernas M, Sjoholm K, Hoffmann JM, Nilsson BE, Hansson M, et al. Gene expression in human brown adipose tissue. Int J Mol Med. 2011;27:227\u201332.","journal-title":"Int J Mol Med."},{"key":"3809_CR49","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1038\/s41598-017-04665-x","volume":"7","author":"Y Takeda","year":"2017","unstructured":"Takeda Y, Harada Y, Yoshikawa T, Dai P. Direct conversion of human fibroblasts to brown adipocytes by small chemical compounds. Sci Rep. 2017;7:4304.","journal-title":"Sci Rep."},{"key":"3809_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1172\/JCI128514","volume":"130","author":"V Del Dotto","year":"2020","unstructured":"Del Dotto V, Ullah F, Di Meo I, Magini P, Gusic M, Maresca A, et al. SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder. J Clin Invest. 2020;130:108\u201325.","journal-title":"J Clin Invest."},{"key":"3809_CR51","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1210\/en.2012-1242","volume":"153","author":"F Tremblay","year":"2012","unstructured":"Tremblay F, Huard C, Dow J, Gareski T, Will S, Richard AM, et al. Loss of coiled-coil domain containing 80 negatively modulates glucose homeostasis in diet-induced obese mice. Endocrinology. 2012;153:4290\u2013303.","journal-title":"Endocrinology."},{"key":"3809_CR52","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","volume":"321","author":"KL Sylvers-Davie","year":"2021","unstructured":"Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab. 2021;321:E493\u2013508.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"3809_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-022-03215-3","volume":"72","author":"L Longhitano","year":"2023","unstructured":"Longhitano L, Vicario N, Forte S, Giallongo C, Broggi G, Caltabiano R, et al. Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma. Cancer Immunol Immunother. 2023;72:1\u201320.","journal-title":"Cancer Immunol Immunother."},{"key":"3809_CR54","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1016\/j.yexcr.2007.05.024","volume":"313","author":"S Amini Nik","year":"2007","unstructured":"Amini Nik S, Ebrahim RP, Van Dam K, Cassiman JJ, Tejpar S. TGF-\u03b2 modulates \u03b2-catenin stability and signaling in mesenchymal proliferations. Exp Cell Res. 2007;313:2887\u201395.","journal-title":"Exp Cell Res."},{"key":"3809_CR55","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bjd.12117","volume":"168","author":"Y Yamaguchi","year":"2013","unstructured":"Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2013;168:717\u201325.","journal-title":"Br J Dermatol."},{"key":"3809_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","volume":"20","author":"LA Organ","year":"2019","unstructured":"Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang\u2019ombe AR, et al. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2019;20:148.","journal-title":"Respir Res."},{"key":"3809_CR57","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10067-019-04720-0","volume":"38","author":"A Fischer","year":"2019","unstructured":"Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38:2673\u201381.","journal-title":"Clin Rheumatol."},{"key":"3809_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.bbrc.2007.09.081","volume":"363","author":"CI Lin","year":"2007","unstructured":"Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, Lee H. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem Biophys Res Commun. 2007;363:1001\u20138.","journal-title":"Biochem Biophys Res Commun."},{"key":"3809_CR59","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340.","journal-title":"Nat Med."},{"key":"3809_CR60","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1194\/jlr.M008045","volume":"52","author":"C Zhao","year":"2011","unstructured":"Zhao C, Sardella A, Chun J, Poubelle PE, Fernandes MJ, Bourgoin SG. TNF-\u03b1 promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines. J Lipid Res. 2011;52:1307\u201318.","journal-title":"J Lipid Res."},{"key":"3809_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.760776","volume":"13","author":"S Majewski","year":"2022","unstructured":"Majewski S, Szewczyk K, Jerczynska H, Milkowska-Dymanowska J, Bialas AJ, Gwadera L, et al. Longitudinal and comparative measures of serum chitotriosidase and YKL-40 in patients with idiopathic pulmonary fibrosis. Front Immunol. 2022;13:760776.","journal-title":"Front Immunol."},{"key":"3809_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/17534259221097835","volume":"28","author":"P Chauvin","year":"2022","unstructured":"Chauvin P, Morzadec C, de Latour B, Llamas-Gutierrez F, Luque-Paz D, Jouneau S, et al. Soluble CD163 is produced by monocyte-derived and alveolar macrophages, and is not associated with the severity of idiopathic pulmonary fibrosis. Innate Immun. 2022;28:138\u201351.","journal-title":"Innate Immun"},{"key":"3809_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102796","author":"I Tomos","year":"2023","unstructured":"Tomos I, Roussis I, Matthaiou AM, Dimakou K. Molecular and genetic biomarkers in idiopathic pulmonary fibrosis: where are we now? Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11102796.","journal-title":"Biomedicines"},{"key":"3809_CR64","doi-asserted-by":"publisher","unstructured":"Karampitsakos T, Tourki B, Jia M, Perrot CY, Visinescu B, Zhao A, et al. The transcriptome of CD14+ CD163\u2212 HLA-DR (low) monocytes predicts mortality in idiopathic pulmonary fibrosis. medRxiv. 2024:2024.08.07.24311386. https:\/\/doi.org\/10.1101\/2024.08.07.24311386.","DOI":"10.1101\/2024.08.07.24311386"},{"key":"3809_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1056121","volume":"9","author":"V Pulito-Cueto","year":"2022","unstructured":"Pulito-Cueto V, Remuzgo-Martinez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernandez D, et al. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis. Front Mol Biosci. 2022;9:1056121.","journal-title":"Front Mol Biosci"},{"key":"3809_CR66","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.yexmp.2014.06.008","volume":"97","author":"M Lishnevsky","year":"2014","unstructured":"Lishnevsky M, Young LC, Woods SJ, Groshong SD, Basaraba RJ, Gilchrist JM, et al. Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB\/n mice. Exp Mol Pathol. 2014;97:128\u201336.","journal-title":"Exp Mol Pathol."},{"key":"3809_CR67","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with idiopathic pulmonary fibrosis. NCT06003426. Available from https:\/\/clinicaltrials.gov\/study\/NCT06003426. Accessed June 11, 2026."},{"key":"3809_CR68","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis. NCT06025578. Available from https:\/\/clinicaltrials.gov\/study\/NCT06025578. Accessed June 11, 2026."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03809-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03809-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:03:34Z","timestamp":1792073014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03809-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3809"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03809-w","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences, Good Clinical Practice, the International Council for Harmonisation, and applicable local requirements. The protocol and documentation provided to patients were reviewed and approved by an independent review board and ethics committees before study initiation. All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TMM has received honoraria or speaker\u2019s fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), CSL Behring, FibroGen, Galapagos, Galecto, GlaxoSmithKline (GSK), IQVIA, Merck, Pliant, Pfizer, Qureight, Roche, Sanofi-Aventis, Structure Therapeutics, Trevi, and Veracyte. NK reports consulting to Boehringer Ingelheim, Pliant, GSK, Three Lake Partners, Merck, AstraZeneca, BMS, Galapagos, Chiesi, Sofinnova, and FibroGen; equity in Pliant; grants from AstraZeneca and BMS; and intellectual property on novel biomarkers and therapeutics in idiopathic pulmonary fibrosis licensed to biotech. MF-C has received honoraria or speaker\u2019s fees or research support from Boehringer Ingelheim, Roche, MSD, AstraZeneca, Pfizer, GSK, Sanofi, and Novartis. FW, CW, and MS are employees and may own stock or shares in BMS. GH, PS, YH, and SS were employees of BMS at the time the study was conducted and may own stock or shares.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"402"}}